Advertisement

Nongenomic Mechanism-Mediated Renal Fibrosis-Decreasing Activity of a Series of PPAR-γ Agonists

  • Hiroyuki Miyachi
Conference paper

Abstract

The number of dialysis patients with chronic kidney disease (CKD) is gradually increasing, especially in Westernized countries. Renal fibrosis is a basic risk factor for CKD, and CKD in turn is considered to be an independent risk factor for cardiovascular disease. CKD is defined as a progressive loss of function over a long period of time. It affects patients worldwide and is associated with a high morbidity and mortality rate. CKD affects more than 13% of the population in the United States (USA) [1] and in Europe [2].

Keywords

Chronic Kidney Disease Renal Fibrosis Alkoxyl Group Estrogen Receptor Agonist Phenylpropanoic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Coresh J, Selvin E, Stevens LA et al (2007) Prevalence of chronic kidney disease in the United States. JAMA 298(17):2038–2047PubMedCrossRefGoogle Scholar
  2. 2.
    Lameire N, Jager K, Van Biesen W et al (2005) Chronic kidney disease: a European perspective. Kidney Int 68(99):S30–S38CrossRefGoogle Scholar
  3. 3.
    Vilayur E, Harris DC (2009) Emerging therapies for chronic kidney disease: what is their role? Nat Rev Nephrol 5(7):375–383PubMedCrossRefGoogle Scholar
  4. 4.
    Leask A (2010) Potential therapeutic targets for cardiac fibrosis: TGF-β, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 106(11):1675–1680PubMedCrossRefGoogle Scholar
  5. 5.
    Mangelsdorf DJ, Evans RM (1995) The nuclear receptor superfamily: the second decade. Cell 83(6):835–839PubMedCrossRefGoogle Scholar
  6. 6.
    Kato S (1998) Transcriptional control by steroid receptor. Nippon Rinsho 56(7):1699–1704PubMedGoogle Scholar
  7. 7.
    Ito I, Hanyu A, Wayama M et al (2010) Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation. J Biol Chem 285(19):14747–14755PubMedCrossRefGoogle Scholar
  8. 8.
    Willson TM (2000) The PPARs: from orphan receptors to drug discovery. J Med Chem 43(4):527–550PubMedCrossRefGoogle Scholar
  9. 9.
    Chevalier RL, Forbes MS, Thornhill BA (2009) Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 75(11):1145–1152PubMedCrossRefGoogle Scholar
  10. 10.
    Camp HS (2003) Thiazolidinediones in diabetes: current status and future outlook. Curr Opin Investig Drugs 4(4):406–411PubMedGoogle Scholar
  11. 11.
    Miyachi H (2007) Design, synthesis, and evaluation of characteristic subtype-selective peroxisome proliferator-activated receptor (PPAR) ligands. Curr Med Chem 14(22):2335–2343PubMedCrossRefGoogle Scholar
  12. 12.
    Oyama T (2009) Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures. Acta Crystallogr D Biol Crystallogr 65(pt 8):786–795PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2012

Authors and Affiliations

  1. 1.Graduate School of Medicine, Dentistry and Pharmaceutical SciencesOkayama UniversityOkayamaJapan

Personalised recommendations